Abstract
Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during phase III trials, have been shown to reduce relapse rates in relapsing-remitting multiple sclerosis (RRMS) as detected by magnetic resonance imaging (MRI). However, the longterm effects of DMDs on MS progression are not very clear; therefore, the aim of this paper is to evaluate the evidence available of the long-term effects of DMDs on reducing the progression of multiple sclerosis. A number of open-label, prospective extensions that followed a cohort of patients enrolled in double-blind, placebo-controlled trials were examined. Methodological difficulties faced in designing a trial of extended duration were hard to overcome, however, and long-term, open-label extensions of interferon and glatiramer acetate failed to show significant beneficial effects in delaying disability progression, questioning the cost-effectiveness of these therapies in the long-term.
Keywords: Multiple sclerosis, demylinating, disease-modifying agents, glatiramer acetate, interferon, relapse
CNS & Neurological Disorders - Drug Targets
Title: Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes
Volume: 8 Issue: 6
Author(s): Oleksandra Katrych, Tessa M. Simone, Shara Azad and Shaker A. Mousa
Affiliation:
Keywords: Multiple sclerosis, demylinating, disease-modifying agents, glatiramer acetate, interferon, relapse
Abstract: Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during phase III trials, have been shown to reduce relapse rates in relapsing-remitting multiple sclerosis (RRMS) as detected by magnetic resonance imaging (MRI). However, the longterm effects of DMDs on MS progression are not very clear; therefore, the aim of this paper is to evaluate the evidence available of the long-term effects of DMDs on reducing the progression of multiple sclerosis. A number of open-label, prospective extensions that followed a cohort of patients enrolled in double-blind, placebo-controlled trials were examined. Methodological difficulties faced in designing a trial of extended duration were hard to overcome, however, and long-term, open-label extensions of interferon and glatiramer acetate failed to show significant beneficial effects in delaying disability progression, questioning the cost-effectiveness of these therapies in the long-term.
Export Options
About this article
Cite this article as:
Katrych Oleksandra, Simone M. Tessa, Azad Shara and Mousa A. Shaker, Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes, CNS & Neurological Disorders - Drug Targets 2009; 8 (6) . https://dx.doi.org/10.2174/187152709789824598
DOI https://dx.doi.org/10.2174/187152709789824598 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytoprotection by Natural and Synthetic Polyphenols in the Heart: Novel Mechanisms and Perspectives
Current Pharmaceutical Design Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Extending Life Using Tissue and Organ Replacement
Current Aging Science Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Safety and Efficacy of Aliskiren in the Treatment of Hypertension and Associated Clinical Conditions
Current Drug Safety Magnesium in Pain Research: State of the Art
Current Medicinal Chemistry Endothelial Progenitor Cells Dysfunction and Senescence: Contribution to Oxidative Stress
Current Cardiology Reviews Regulation of Ion Channels, Cellular Carriers and Na(+)/K(+)/ATPase by Janus Kinase 3
Current Medicinal Chemistry Can Tea Consumption be a Safe and Effective Therapy Against Diabetes Mellitus-Induced Neurodegeneration?
Current Neuropharmacology A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design New Approaches in the Management of Septic Shock
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Current Medicinal Chemistry Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Percutaneous Valve Interventions
Current Cardiology Reviews From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews